Harford Simon N.R. 4

What Happened

Simon Harford, Chief Financial Officer of Amicus Therapeutics (FOLD), disposed of company equity on 2026-04-27 in connection with BioMarin’s acquisition of Amicus. He surrendered 143,595 shares (108,478 common shares + 35,117 RSUs that vested at closing) at $14.50 per share for proceeds of $2,082,128. In addition, a number of stock options were cancelled and converted into cash payments (amounts not reported on the Form 4).

Key Details

• Transaction date: 2026-04-27. Transaction type: Disposition to issuer (code D) in connection with the merger.
• Reported cash proceeds for shares: 143,595 shares × $14.50 = $2,082,128.
• Other reported dispositions (options) show "N/A" for price/value on the Form 4; footnotes state each option was vested and cancelled and converted into a cash payment equal to (14.50 − option exercise price) × number of shares underlying the option. Cash amounts for those conversions were not disclosed in the filing.
• The 143,595 total equals 108,478 common shares + 35,117 RSUs that vested at closing (per footnote).
• Shares owned following the transaction are not provided in the supplied data.
• Filing date: 2026-04-27; no late filing indication in the provided information.

Context

• These were dispositions to the issuer tied to the company being acquired by BioMarin, not open-market sales. Such transactions commonly occur at deal closing when RSUs vest and options are cashed out or cancelled.
• The option-related entries are derivative transactions: vested options were cancelled and converted to a cash settlement based on the merger price less the exercise price. The Form 4 lists those as "Disposed" with values marked N/A, so the exact cash realized from options isn't shown here.
• This is a routine corporate-transaction liquidity event rather than an independent trading decision by the insider; it should be interpreted as settlement under the merger terms, not necessarily a signal about future company prospects.